Deals In Depth: May 2011
Executive Summary
With a three-way tie, deals by Glenmark/Sanofi, Elan/Proteostasis, and Mundipharma/Allos were each valued at $50 million. Takeda expanded into Europe and emerging markets through its $14 billion buy of Nycomed, while PE firm Cinven scored big when it sold IVD investment Phadia to Thermo Fisher Scientific for $3.5 billion. Shanghai Pharma's $1.9 billion IPO on the Hong Kong Stock Exchange pushed biopharma financing in May up to $2.8 billion. Late VC financings in the device sector made up the majority of fundraising, which totaled $469 million.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.